As we mark the anniversary of bioXcelerate AI, we are delighted to invite you to an exclusive evening celebrating the unveiling of our DiscoveryX Platform. This event will reflect on what we’ve achieved over the past year and offer a first look at how our latest technology is transforming decision-making in early-stage drug discovery.
Drug development remains high-risk and resource-intensive. Nearly 90% of candidates fail in clinical trials, and bringing a single drug to market now costs more than $2.6 billion on average. A major contributor to this is the difficulty of making confident, data-driven decisions early in the process, particularly when information is fragmented, unstructured, or underutilised.
Introducing the DiscoveryX Platform
bioXcelerate AI is dedicated to improving early-stage success in pharma and biotech by turning complex scientific data into actionable insight. Our DiscoveryX Platform combines proprietary machine learning, advanced analytics, and modern cloud infrastructure to help teams make faster, smarter, and more confident decisions, ultimately improving outcomes for both R&D teams and patients.
Whether used alone or alongside our expert services, bioXcelerate is here to support data-driven discovery from day one.
What to Expect
The evening will give you a clear view of how our platform delivers real impact – not just technically, but in how it streamlines workflows, sharpens prioritisation, and boosts return on research investment.
You’ll see how the platform can help you:
- Integrate and extract value from diverse data assets
- Prioritise targets with greater confidence, reducing downstream attrition
- De-risk decision-making and maximise R&D ROI
- Accelerate the path from discovery to clinic
We’ll also share insights from our team and early adopters, and show how this technology can support your discovery teams in meeting today’s toughest R&D challenges.
